克隆性造血与血液透析ESKD患者心血管事件:VIVALDI研究结果
CH与卒中、心肌梗死、3点MACE或静脉血栓栓塞风险无关,但与血管通路血栓风险升高相关;非DNMT3A CH患者全因死亡风险升高。
要点
- 血透ESKD患者CH患病率为7%,以DNMT3A突变最常见。
- CH与卒中、心肌梗死、MACE及静脉血栓栓塞风险无关。
- CH与血管通路血栓风险升高相关,非DNMT3A CH与全因死亡风险升高相关。
核心结论
- 7%的血液透析ESKD患者存在CH,CH与卒中、心肌梗死或静脉血栓栓塞无关,但与血管通路血栓相关。
研究设计与样本
- 研究纳入时采集外周血DNA筛查CH相关突变,并评估CH与心血管结局的关联。
主要发现
- 在40例患者(7%)中检出44个CH相关变异,最常见于DNMT3A(43%)、TET2(18%)和TP53(18%)。
- CH患者年龄更大(75岁 vs 65岁,P<0.001),累积透析时间更长(4年 vs 2年,P=0.02)。
- CH与卒中(SHR 0.25,95%CI 0.04–1.84)、心肌梗死(SHR 0.90,95%CI 0.20–4.13)、3点MACE(SHR 0.65,95%CI 0.33–1.28)及静脉血栓栓塞(SHR 1.68,95%CI 0.35–8.12)风险无关。
- CH患者血管通路血栓风险更高(SHR 2.47,95%CI 1.34–4.56),非DNMT3A CH患者全因死亡风险更高(HR 1.71,95%CI 1.03–2.85)。
临床怎么用
- 在血透ESKD患者中,CH检测可能有助于识别血管通路血栓及死亡风险较高的亚组。
- CH的存在不应作为卒中、心肌梗死或静脉血栓栓塞风险增高的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The prevalence of clonal hematopoiesis in patients with ESKD on hemodialysis was 7%. Clonal hematopoiesis was not associated with stroke, myocardial infarction, or venous thromboembolism. Clonal hematopoiesis was associated with vascular access thrombosis. BACKGROUND: Patients with ESKD on hemodialysis are at high risk for cardiovascular complications. Clonal hematopoiesis (CH), defined as clonal expansion of hematopoietic stem cells due to acquired mutations, was shown to be associated with cardiovascular events, but this association was not yet assessed in patients with impaired kidney function. METHODS: Our aim was to investigate the CH-associated mutation prevalence in patients with ESKD on hemodialysis included in the population-based prospective observational Vienna InVestigation of AtriaL Fibrillation and thromboembolism in hemoDIalysis (VIVALDI) study and to assess an association between CH and cardiovascular outcomes. Peripheral blood DNA samples collected at study inclusion were screened for CH-associated mutations. RESULTS: Five hundred seventy patients were analyzed (median age, 66 years [interquartile range [IQR], 55–75]; 37.1% female). The median follow-up time was 39 months (IQR, 35–41). We detected 44 CH-associated variants in 40 patients (7%), most commonly in the gene DNMT3A (43%), TET2 (18%), and TP53 (18%). Patients with CH were older (75 [IQR, 68–80] versus 65 [IQR, 54–74] years, P < 0.001) and had longer cumulative dialysis time (4 [IQR, 1.0–4.0] versus 2 [IQR, 1.9–5.5] years, P = 0.02). CH was not associated with stroke (subdistribution hazard ratio [SHR], 0.25; 95% confidence interval [CI], 0.04 to 1.84), myocardial infarction (SHR, 0.90; 95% CI, 0.20 to 4.13), three-point major adverse cardiovascular events (SHR, 0.65; 95% CI, 0.33 to 1.28), or venous thromboembolism (SHR, 1.68; 95% CI, 0.35 to 8.12) risk. Patients with CH exhibited a higher risk of vascular access thrombosis (SHR, 2.47; 95% CI, 1.34 to 4.56) and patients with non-DNMT3A CH present with a higher all-cause mortality risk (hazard ratio, 1.71; 95% CI, 1.03 to 2.85). CONCLUSIONS: Seven percent of patients with ESKD on hemodialysis presented with CH. There was no association between CH and stroke, myocardial infarction, or venous thromboembolism. CH was associated with vascular access thrombosis.
引用
- Englisch C, Königsbrügge O, Vostatek R, et al. Clonal Hematopoiesis and Cardiovascular Events in Patients with ESKD on Hemodialysis: Results from the VIVALDI Study. Clin J Am Soc Nephrol. 2025. PMID: 40892483. doi:10.2215/CJN.0000000833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。